Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMBI-AD adjuvant dabrafenib + trametinib in resected high-risk BRAF V600-mutant melanoma
2012-001266-15Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dabrafenib + trametinib and trametinib in cutaneous melanoma (CM) (2 arms), sponsored by Novartis. Primary endpoint: Relapse-free survival. Started Oct 2012; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on 2012-001266-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001266-15.